Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba. This product, discovered by Basilea and licensed to a global partner for commercialization, is approved for the treatment of invasive aspergillosis and mucormycosis in several regions, including Europe and North America. In the anti‐infective area, Basilea has also advanced cefiderocol, a novel siderophore cephalosporin antibiotic, through clinical development to address multidrug‐resistant Gram‐negative bacterial infections.
In oncology, Basilea’s pipeline includes small‐molecule compounds designed to inhibit key pathways in solid tumors. Among these are proprietary kinase inhibitors in clinical trials targeting skin and colorectal cancers. The company maintains a robust R&D collaboration model, partnering with academic institutions and pharmaceutical companies to co-develop and out-license assets, thereby extending its global reach without a large commercial infrastructure.
Founded in 2000, Basilea operates manufacturing and R&D facilities in Switzerland and has established regional offices and partnerships across Europe, North America and Asia. Under the leadership of Chief Executive Officer Dr. Michael Heider, the company continues to pursue strategic alliances to advance its pipeline and bring novel therapies to patients with high-unmet medical needs.
AI Generated. May Contain Errors.
